Francesco Galimi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5238612/publications.pdf

Version: 2024-02-01

19 papers	3,031 citations	430874 18 h-index	752698 20 g-index
21 all docs	21 docs citations	21 times ranked	5775 citing authors

#	Article	IF	Citations
1	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	9.4	818
2	Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
3	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	6.4	266
4	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery, 2015, 5, 832-841.	9.4	250
5	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nature Communications, 2017, 8, 15107.	12.8	213
6	Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clinical Cancer Research, 2012, 18, 2515-2525.	7.0	172
7	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
8	Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations. Clinical Cancer Research, 2011, 17, 3146-3156.	7.0	113
9	IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine, 2015, 7, 272ra12.	12.4	100
10	Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Science Signaling, 2009, 2, ra80.	3.6	84
11	Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene, 2013, 32, 1428-1440.	5.9	53
12	MACC1 mRNA Levels Predict Cancer Recurrence After Resection of Colorectal Cancer Liver Metastases. Annals of Surgery, 2013, 257, 1089-1095.	4.2	44
13	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cellâ€“like phenotype. Science Translational Medicine, 2020, 12, .	12.4	40
14	Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors. Clinical Cancer Research, 2010, 16, 3933-3943.	7.0	39
15	Met inhibition revokes IFNÎ³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536.	6.4	34
16	The hepatocyte growth factor and its receptor. Stem Cells, 1993, 11, 22-30.	3.2	33
17	A Correction to the Research Article Titled: "Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction" by A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino. Science Signaling, 2009, 2, er11.	3.6	23
18	A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. International Journal of Cancer, 2012, 130, 1357-1366.	5.1	21

#	Article	IF	Citations
19	Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. Liver, 1994, 14, 213-219.	0.1	18